References
- IDF Diabetes Atlas, 9th ed., International Diabetes Federation Diabetes Atlas, 2019, Avaialable at https://www.diabetesatlas.org/en/ [accessed 15 August 2021].
- Y. Huang, X. Cai, W. Mai, M. Li, and Y. Hu, Association between prediabetes and risk of cardiovascular disease and all cause mortality: Systematic review and meta-analysis, BMJ 355 (2016), pp. i5953. doi:https://doi.org/10.1136/bmj.i5953.
- A.G. Tabák, C. Herder C, W. Rathmann, E.J. Brunner, and M. Kivimäki, Prediabetes: A high-risk state for diabetes development, Lancet 379 (2012), pp. 2279–2290. doi:https://doi.org/10.1016/S0140-6736(12)60283-9.
- Y. Heianza, S. Hara, Y. Arase, K. Saito, K. Fujiwara, H. Tsuji, S. Kodama, S.D. Hsieh, Y. Mori, H. Shimano, N. Yamada, K. Kosaka, and H. Sone, HbA1c 5·7-6·4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): A longitudinal cohort study, Lancet 378 (2011), pp. 147–155. doi:https://doi.org/10.1016/S0140-6736(11)60472-8.
- J. Yeboah, A.G. Bertoni, D.M. Herrington, W.S. Post, and G.L. Burke, Impaired fasting glucose and the risk of incident diabetes mellitus and cardiovascular events in an adult population: MESA (Multi-Ethnic Study of Atherosclerosis), J. Am. Coll. Cardiol. 58 (2011), pp. 140–146. doi:https://doi.org/10.1016/j.jacc.2011.03.025.
- M.J. Davies, D.A. D’Alessio, J. Fradkin, W.N. Kernan, C. Mathieu, G. Mingrone, P. Rossing, A. Tsapas, D.J. Wexler, and J.B. Buse, Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetes Care 41 (2018), pp. 2669–2701. doi:https://doi.org/10.2337/dci18-0033.
- G. Ferrannini and L. Rydén, Sodium-glucose transporter 2 inhibition and cardiovascular events in patients with diabetes: Information from clinical trials and observational real-world data, Clin. Sci. (Lond) 132 (2018), pp. 2003–2012. doi:https://doi.org/10.1042/CS20171374.
- S. Dellepiane, M.B. Nasr, E. Assi, V. Usuelli, T. Letizia, F. D’Addio, G.V. Zuccotti, and P. Fiorina, Sodium glucose cotransporters inhibitors in type 1 diabetes, Pharmacol. Res. 133 (2018), pp. 1–8. doi:https://doi.org/10.1016/j.phrs.2018.04.018.
- H.J. Heerspink, B.A. Perkins, D.H. Fitchett, M. Husain, and D.Z. Cherney, Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: Cardiovascular and kidney effects, potential mechanisms, and clinical applications, Circulation 134 (2016), pp. 752–772. doi:https://doi.org/10.1161/CIRCULATIONAHA.116.021887.
- J.R. Ehrenkranz, N.G. Lewis, C.R. Kahn, and J. Roth, Phlorizin: A review, Diabetes Metab. Res. Rev. 21 (2005), pp. 31–38. doi:https://doi.org/10.1002/dmrr.532.
- A. Oku, K. Ueta, K. Arakawa, T. Ishihara, M. Nawano, Y. Kuronuma, M. Matsumoto, A. Saito, K. Tsujihara, M. Anai, T. Asano, Y. Kanai, and H. Endou, T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes, Diabetes 48 (1999), pp. 1794–1800. doi:https://doi.org/10.2337/diabetes.48.9.1794.
- K. Katsuno, Y. Fujimori, Y. Takemura, M. Hiratochi, F. Itoh, Y. Komatsu, H. Fujikura, and M. Isaji, Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level, J. Pharmacol. Exp. Ther. 320 (2007), pp. 323–330. doi:https://doi.org/10.1124/jpet.106.110296.
- Y. Fujimori, K. Katsuno, I. Nakashima, Y. Ishikawa-Takemura, H. Fujikura, and M. Isaji, Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models, J. Pharmacol. Exp. Ther. 327 (2008), pp. 268–276. doi:https://doi.org/10.1124/jpet.108.140210.
- W. Meng, B.A. Ellsworth, A.A. Nirschl, P.J. McCann, M. Patel, R.N. Girotra, G. Wu, P.M. Sher, E.P. Morrison, S.A. Biller, R. Zahler, P.P. Deshpande, A. Pullockaran, D.L. Hagan, N. Morgan, J.R. Taylor, M.T. Obermeier, W.G. Humphreys, A. Khanna, L. Discenza, J.G. Robertson, A. Wang, S. Han, J.R. Wetterau, E.B. Janovitz, O.P. Flint, J.M. Whaley, and W.N. Washburn, Discovery of dapagliflozin: A potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes, J. Med. Chem. 51 (2008), pp. 1145–1149. doi:https://doi.org/10.1021/jm701272q.
- S. Nomura, S. Sakamaki, M. Hongu, E. Kawanishi, Y. Koga, T. Sakamoto, Y. Yamamoto, K. Ueta, H. Kimata, K. Nakayama, and M. Tsuda-Tsukimoto, Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus (1), J. Med. Chem. 53 (2010), pp. 6355–6360. doi:https://doi.org/10.1021/jm100332n.
- M. Imamura, K. Nakanishi, T. Suzuki, K. Ikegai, R. Shiraki, T. Ogiyama, T. Murakami, E. Kurosaki, A. Noda, Y. Kobayashi, M. Yokota, T. Koide, K. Kosakai, Y. Ohkura, M. Takeuchi, H. Tomiyama, and M. Ohta, Discovery of Ipragliflozin (ASP1941): A novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus, Bioorg. Med. Chem. 20 (2012), pp. 3263–3279. doi:https://doi.org/10.1016/j.bmc.2012.03.051.
- N.C. Goodwin, R. Mabon, B.A. Harrison, M.K. Shadoan, Z.Y. Almstead, Y. Xie, J. Healy, L.M. Buhring, C.M. DaCosta, J. Bardenhagen, F. Mseeh, F. Q. Liu, A. Nouraldeen, A.G. Wilson, S.D. Kimball, D.R. Powell, and D.B. Rawlins, Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes, J. Med. Chem. 52 (2009), pp. 6201–6204. doi:https://doi.org/10.1021/jm900951n.
- V. Mascitti, B.A. Thuma, A.C. Smith, R.P. Robinson, T. Brandt, A.S. Kalgutkar, T.S. Maurer, B. Samasa, and R. Sharma, On the importance of synthetic organic chemistry in drug discovery: Reflections on the discovery of antidiabetic agent ertugliflozin, Medchemcomm 4 (2013), pp. 101–111. doi:https://doi.org/10.1039/C2MD20163A.
- W. Zhang, A. Welihinda, J. Mechanic, H. Ding, L. Zhu, Y. Lu, Z. Deng, Z. Sheng, B. Lv, Y. Chen, J.Y. Roberge, B. Seed, and Y.X. Wang, EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA1c levels in db/db mice and prolongs the survival of stroke-prone rats, Pharmacol. Res. 63 (2011), pp. 284–293. doi:https://doi.org/10.1016/j.phrs.2011.01.001.
- Y. Wang, Y. Lou, J. Wang, D. Li, H. Chen, T. Zheng, C. Xia, X. Song, T. Dong, J. Li, and H. Liu, Design, synthesis and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes, Eur. J. Med. Chem. 180 (2019), pp. 398–416. doi:https://doi.org/10.1016/j.ejmech.2019.07.032.
- H. Kakinuma, T. Oi, Y. Hashimoto-Tsuchiya, M. Arai, Y. Kawakita, Y. Fukasawa, I. Iida, N. Hagima, H. Takeuchi, Y. Chino, J. Asami, L. Okumura-Kitajima, F. Io, D. Yamamoto, N. Miyata, T. Takahashi, S. Uchida, and K. Yamamoto, (1 S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio- d -glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment, J. Med. Chem. 53 (2010), pp. 3247–3261. doi:https://doi.org/10.1021/jm901893x.
- S. Kuroda, Y. Kobashi, T. Oi, K. Kawabe, F. Shiozawa, L. Okumura-Kitajima, M. Sugisaki-Kitano, F. Io, K. Yamamoto, and H. Kakinuma, Discovery of potent, low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor SGL5213 for type 2 diabetes treatment, Bioorg. Med. Chem. 27 (2019), pp. 394–409. doi:https://doi.org/10.1016/j.bmc.2018.12.015.
- S. Kuroda, Y. Kobashi, T. Oi, H. Amada, L. Okumura-Kitajima, F. Io, K. Yamamto, and H. Kakinuma, Discovery of a potent, low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor (TP0438836) for the treatment of type 2 diabetes, Bioorg. Med. Chem. Lett. 28 (2018), pp. 3534–3539. doi:https://doi.org/10.1016/j.bmcl.2018.09.035.
- G.H. Kuo, M.D. Gaul, Y. Liang, J.Z. Xu, F. Du, P. Hornby, G. Xu, J. Qi, N. Wallace, S. Lee, E. Grant, W.V. Murray, and K. Demarest, Synthesis and biological evaluation of benzocyclobutane-C-glycosides as potent and orally active SGLT1/SGLT2 dual inhibitors, Bioorg. Med. Chem. Lett. 28 (2018), pp. 1182–1187. doi:https://doi.org/10.1016/j.bmcl.2018.02.057.
- G. Xu, M.D. Gaul, G.H. Kuo, F. Du, J.Z. Xu, N. Wallace, S. Hinke, T. Kirchner, J. Silva, N.D. Huebert, S. Lee, W. Murray, Y. Liang, and K. Demarest, Design, synthesis and biological evaluation of (2S,3R,4R,5S,6R)-5-fluoro-6-(hydroxymethyl)-2-aryltetrahydro-2H-pyran-3,4-diols as potent and orally active SGLT dual inhibitors, Bioorg. Med. Chem. Lett. 28 (2018), pp. 3446–3453. doi:https://doi.org/10.1016/j.bmcl.2018.09.025.
- A. Baldi, Computational approaches for drug design and discovery: An overview, Syst. Rev. Pharm. 1 (2010), pp. 99–105. doi:https://doi.org/10.4103/0975-8453.59519.
- A. Jain, Computer aided drug design, J. Phys. Conf. Ser. 884 (2017), pp. 012072. doi:https://doi.org/10.1088/1742-6596/884/1/012072.
- J.S. Smith, A.E. Roitberg, and O. Isayev, Transforming computational drug discovery with machine learning and AI, ACS Med. Chem. Lett. 9 (2018), pp. 1065–1069. doi:https://doi.org/10.1021/acsmedchemlett.8b00437.
- M.H. Baig, K. Ahmad, S. Roy, J.M. Ashraf, M. Adil, M.H. Siddiqui, S. Khan, M.A. Kamal, I. Provaznik, and I. Choi, Computer aided drug design: Success and limitations, Curr. Pharm. Des. 22 (2016), pp. 572–581. doi:https://doi.org/10.2174/1381612822666151125000550.
- S.J. Macalino, V. Gosu, S. Hong, and S. Choi, Role of computer-aided drug design in modern drug discovery, Arch. Pharm. Res. 38 (2015), pp. 1686–1701. doi:https://doi.org/10.1007/s12272-015-0640-5.
- E.N. Muratov, J. Bajorath, R.P. Sheridan, I.V. Tetko, D. Filimonov, V. Poroikov, T.I. Oprea, I.I. Baskin, A. Varnek, A. Roitberg, O. Isayev, S. Curtalolo, D. Fourches, Y. Cohen, A. Aspuru-Guzik, D.A. Winkler, D. Agrafiotis, A. Cherkasov, and A. Tropsha, QSAR without borders, Chem. Soc. Rev. 49 (2020), pp. 3525–3564.
- A. Cherkasov, E.N. Muratov, D. Fourches, A. Varnek, I.I. Baskin, M. Cronin, J. Dearden, P. Gramatica, Y.C. Martin, R. Todeschini, V. Consonni, V.E. Kuz’min, R. Cramer, R. Benigni, C. Yang, J. Rathman, L. Terfloth, J. Gasteiger, A. Richard, and A. Tropsha, QSAR modeling: Where have you been? Where are you going to? J. Med. Chem. 57 (2014), pp. 4977–5010.
- T. Fujita and D.A. Winkler, Understanding the roles of the “two QSARs”, J. Chem. Inf. Model. 56 (2016), pp. 269–274. doi:https://doi.org/10.1021/acs.jcim.5b00229.
- J. Huang and X. Fan, Why QSAR fails: An empirical evaluation using conventional computational approach, Mol. Pharm. 8 (2011), pp. 600–608. doi:https://doi.org/10.1021/mp100423u.
- N. Chirico and P. Gramatica, Real external predictivity of QSAR models. Part 2. New intercomparable thresholds for different validation criteria and the need for scatter plot inspection, J. Chem. Inf. Model. 52 (2012), pp. 2044–2058.
- P. Gramatica, S. Cassani, P.P. Roy, S. Kovarich, C.W. Yap, and E. Papa, QSAR modeling is not “Push a button and find a correlation”: A case study of toxicity of (Benzo-)triazoles on Algae, Mol. Inform. 31 (2012), pp. 817–835.
- T.M. Martin, P. Harten, D.M. Young, E.N. Muratov, A. Golbraikh, H. Zhu, and A. Tropsha, Does rational selection of training and test sets improve the outcome of QSAR modeling? J. Chem. Inf. Model. 52 (2012), pp. 2570–2578. doi:https://doi.org/10.1021/ci300338w.
- V.H. Masand, D.T. Mahajan, G.M. Nazeruddin, T.B. Hadda, V. Rastija, and A.M. Alfeefy, Effect of information leakage and method of splitting (rational and random) on external predictive ability and behavior of different statistical parameters of QSAR model, Med. Chem. Res. 24 (2015), pp. 1241–1264. doi:https://doi.org/10.1007/s00044-014-1193-8.
- P. Gramatica, On the development and validation of QSAR models, Meth. Mol. Biol. 930 (2013), pp. 499–526.
- X. Zhao, B. Sun, H. Zheng, J. Liu, L. Qian, X. Wan, and H. Lou, Synthesis and biological evaluation of 6-hydroxyl C-aryl glucoside derivatives as novel sodium glucose co-transporter 2 (SGLT2) inhibitors, Bioorg. Med. Chem. Lett. 28 (2018), pp. 2201–2205. doi:https://doi.org/10.1016/j.bmcl.2018.04.070.
- G. Xu, B. Lv, J.Y. Roberge, B. Xu, J. Du, J. Dong, Y. Chen, K. Peng, L. Zhang, X. Tang, Y. Feng, M. Xu, W. Fu, W. Zhang, L. Zhu, Z. Deng, Z. Sheng, A. Welihinda, and X. Sun, Design, synthesis, and biological evaluation of deuterated C-aryl glycoside as a potent and long-acting renal sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes, J. Med. Chem. 57 (2014), pp. 1236–1251. doi:https://doi.org/10.1021/jm401780b.
- S. Nomura, Y. Yamamoto, Y. Matsumura, K. Ohba, S. Sakamaki, H. Kimata, K. Nakayama, C. Kuriyama, Y. Matsushita, K. Ueta, and M. Tsuda-Tsukimoto, Novel indole-N-glucoside, TA-1887 as a sodium glucose cotransporter 2 inhibitor for treatment of type 2 diabetes, ACS Med. Chem. Lett. 5 (2014), pp. 51–55. doi:https://doi.org/10.1021/ml400339b.
- V.H. Masand and V. Rastija, PyDescriptor: A new PyMOL plugin for calculating thousands of easily understandable molecular descriptors, Chemom. Intell. Lab. Syst. 169 (2017), pp. 12–18. doi:https://doi.org/10.1016/j.chemolab.2017.08.003.
- P. Gramatica, S. Cassani, and N. Chirico, QSARINS-chem: Insubria datasets and new QSAR/QSPR models for environmental pollutants in QSARINS, J. Comput. Chem. 35 (2014), pp. 1036–1044. doi:https://doi.org/10.1002/jcc.23576.
- P. Gramatica, N. Chirico, E. Papa, S. Cassani, and S. Kovarich, QSARINS: A new software for the development, analysis, and validation of QSAR MLR models, J. Comput. Chem. 34 (2013), pp. 2121–2132. doi:https://doi.org/10.1002/jcc.23361.
- A.K. Saxena and P. Prathipati, Comparison of MLR, PLS and GA-MLR in QSAR analysis, SAR QSAR Environ. Res. 14 (2003), pp. 433–445. doi:https://doi.org/10.1080/10629360310001624015.
- K. Roy, S. Kar, and P. Ambure, On a simple approach for determining applicability domain of QSAR models, Chemom. Intell. Lab. Syst. 145 (2015), pp. 22–29. doi:https://doi.org/10.1016/j.chemolab.2015.04.013.
- T.M. de Assis, G.C. Gajo, L.C. de Assis, L.S. Garcia, D.R. Silva, T.C. Ramalho, and E.F. da Cunha, QSAR models guided by molecular dynamics applied to human glucokinase activators, Chem. Biol. Drug Des. 87 (2016), pp. 455–466. doi:https://doi.org/10.1111/cbdd.12683.
- P. Gramatica, Principles of QSAR models validation: Internal and external, QSAR Comb. Sci. 26 (2007), pp. 694–701. doi:https://doi.org/10.1002/qsar.200610151.
- A. Arwansyah, A.R. Arif, G. Syahputra, S. Sukarti, and I. Kurniawan, Theoretical studies of thiazolyl-pyrazoline derivatives as promising drugs against malaria by QSAR modelling combined with molecular docking and molecular dynamics simulation, Mol. Simul. 47 (2021), pp. 998–1001. doi:https://doi.org/10.1080/08927022.2021.1935926.